Immunocore announces first patient dosed in the Phase 1 trial of IMC-P115C, a half-life extended (HLE) ImmTAC candidate in patients with tumors that express PRAME
Portfolio Pulse from
Immunocore has dosed the first patient in a Phase 1 trial for IMC-P115C, a new HLE ImmTAC candidate targeting tumors expressing PRAME.
December 23, 2024 | 12:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Immunocore has initiated a Phase 1 trial for its new HLE ImmTAC candidate, IMC-P115C, marking a significant step in its oncology pipeline.
The initiation of a Phase 1 trial for IMC-P115C is a positive development for Immunocore, indicating progress in their oncology pipeline. This could lead to increased investor interest and a potential rise in stock price.
CONFIDENCE 95
IMPORTANCE 80
RELEVANCE 90